Answers are grounded in this paper and cite their sources.
Optimizing sample treatment improves assay specificity in detecting anti-drug antibodies, reducing target interference.
Background Drug bridging immunoassays are widely employed as the standard approach for detecting anti-drug antibodies (ADAs) in the development of new biological entities. A major challenge in these assays is mitigating target interference, particularly when the soluble target exists in dimeric forms, which can result in false positive signals and compromise assay specificity.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: